Trulicity vs. Qsymia
Trulicity and Qsymia differ in mechanism and purpose. Trulicity is a GLP-1 agonist for type 2 diabetes management, providing HbA1c reductions and modest weight loss. Qsymia, a combination of phentermine and topiramate, is for chronic weight management, achieving greater weight loss but without glucose-related benefits. Trulicity causes nausea, while Qsymia may lead to insomnia and mood changes due to its stimulant components. Trulicity costs $875/month, significantly more than Qsymia’s $300/month. Neither drug currently faces shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, diarrhea, vomiting, fatigue, and decreased appetite.
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Phentermine suppresses appetite by stimulating the release of norepinephrine in the brain; topiramate enhances feelings of fullness and alters taste perceptions, reducing food intake.
Common Side Effects
Dry mouth, insomnia, constipation, dizziness, and tingling in hands or feet.
Serious Potential Side Effects
Increased heart rate, mood changes, suicidal thoughts, and memory/concentration difficulties, dependency and abuse of medication